Takeda Pharmaceutical Co. Newsletter
-
Innovent seals lucrative $11.4b deal with Takeda Pharmaceutical
22 Oct 2025 03:37 GMT
… announced a sweeping partnership with Takeda Pharmaceutical, with a total potential transaction …
-
Complement 3 Glomerulopathy Market Poised for Phenomenal Expansion at a CAGR of 37.2% During the Forecast Period (2025–2034) Owing to the Launch of Promising Therapies Targeting C3, C5, MASP-3, and RNAi | DelveInsight
22 Oct 2025 17:00 GMT
… glomerulonephritis companies, including Alentis Therapeutics, Takeda Pharmaceutical, Biogen, Novartis, Nkarta, Vertex Pharmaceuticals … glomerulonephritis companies, including Alentis Therapeutics, Takeda Pharmaceutical, Biogen, Novartis, Nkarta, Vertex …
-
Flagship bets again on AI with Expedition
22 Oct 2025 14:03 GMT
… . Pharmas such as Eli Lilly, Takeda Pharmaceutical and Bristol Myers Squibb have …
-
Futures Flat As Gold Selloff Extends
22 Oct 2025 13:10 GMT
… of a strategic collaboration with Takeda Pharmaceutical to develop cancer therapies.
Meituan …
-
Accounting for Comorbidity in Etiologic Research
22 Oct 2025 07:56 GMT
… .K. is currently employed by Takeda Pharmaceutical Company outside of the submitted …
-
China's Innovent signs $11.4 billion cancer therapy deal with Japan's Takeda
22 Oct 2025 01:07 GMT
… billion deal with Japan’s Takeda Pharmaceutical Co to accelerate the development …
-
Galapagos to Wind Down Cell Therapy Business After Search for a Buyer Comes Up Empty
22 Oct 2025 01:16 GMT
… the beginning of the month, Takeda Pharmaceutical announced reprioritization of its portfolio …
-
Weight Loss Drugs Market Set to Reach USD 50.26 Billion by 2032, Driven by Prescription Drug Adoption and Breakthrough Formulations – SNS Insider
20 Oct 2025 15:28 GMT
… Pharmaceuticals, Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries …
-
Bank of America Upgraded, Allstate Downgraded: Updated Rankings on Top Blue-Chip Stocks
20 Oct 2025 15:28 GMT
… ADR
B
C
B
TAK
Takeda Pharmaceutical Co. Ltd. Sponsored ADR
B …
-
BioCryst’s $700M Astria Acquisition Gives It a Shot to Beat Larger Rivals in Rare Disease HAE
19 Oct 2025 23:29 GMT
… market is becoming more competitive. Takeda Pharmaceutical dominates with Takhzyro, a kallikrein …